Biological
ANXV
ANXV is a biological therapy with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
completed267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
NCT07259928
completedphase_2
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
NCT05532735
completedphase_1
First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers
NCT04850339
Clinical Trials (3)
Showing 3 of 3 trials
NCT07259928Phase 2
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
NCT05532735Phase 2
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
NCT04850339Phase 1
First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3